Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Completed 11Terminated 8Recruiting 4Active not recruiting 3

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Breast 2Gynecologic 1

Conditions

Multiple Myeloma 87Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 16Burkitt Lymphoma 13Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Biphenotypic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Waldenstrom Macroglobulinemia 3Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nausea 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Brain Neoplasms 3Renal Insufficiency 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2

Interventions

pembrolizumab 117Carboplatin 104Pemetrexed 93Cisplatin 59Paclitaxel 49Drug Therapy 41osimertinib 40Nivolumab 40Docetaxel 37Specimen Handling 33Magnetic Resonance Spectroscopy 28Bevacizumab 26durvalumab 22Gemcitabine 22cemiplimab 21130-nm albumin-bound paclitaxel 21Radiotherapy 20tislelizumab 19Radiosurgery 19atezolizumab 17aflutinib 15Immunotherapy 15Cetuximab 15Platinum Compounds 13Ipilimumab 13Immune Checkpoint Inhibitors 13Biopsy 12Standard of Care 11Surgical Procedures, Operative 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Non-Small-Cell Lung × Dexamethasone × Clear all
NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07213375 2026-01-07

DEXTER

Rigshospitalet, Denmark

Phase 2/3 Recruiting
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06974604 2025-10-24

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Brown University

Phase 2 Recruiting
60 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡